预约演示
更新于：2025-04-14
Estradiol Valerate
戊酸雌二醇
更新于：2025-04-14
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H32O3 |
InChIKeyRSEPBGGWRJCQGY-RBRWEJTLSA-N |
CAS号979-32-8 |
关联
64
项与 戊酸雌二醇 相关的临床试验CTR20244799
中国健康绝经后女性受试者空腹及餐后状态下口服戊酸雌二醇片的随机、开放、两序列、两周期双交叉设计生物等效性试验
CTRI/2024/06/069694
An Open Label, Prospective, Randomized, Multi-Center, Three-arm Clinical Trial to Compare the Efficacy and Safety of Estradiol hemihydrate Tablet 2mg Vs Estradiol Valerate Vs Estradiol hemihydrate Tablet (2 mg) plus Estradiol TG (Topical Gel) in Patients who are Candidate for Frozen Embryo Transfer (FET) Cycle - NIL
CTRI/2024/06/068270
Comparing The Effect Of Estradiol Valerate And Conjugated Equine Estrogen In The Patients With Premature Ovarian Insufficiency A Randomized Control Trial - NIL
100 项与 戊酸雌二醇 相关的临床结果
登录后查看更多信息
100 项与 戊酸雌二醇 相关的转化医学
登录后查看更多信息
100 项与 戊酸雌二醇 相关的专利（医药）
登录后查看更多信息
2,457
项与 戊酸雌二醇 相关的文献（医药）2025-04-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Longitudinal changes of automated volumetric breast density with postmenopausal hormone therapy
Article
作者: Kim, Seok Hyun ; Chang, Jung Min ; Kim, Hoon ; Hong, Yun Soo ; Ku, Seung-Yup ; Kim, Sung Woo ; Suh, Chang Suk ; Han, Ji Yeon
OBJECTIVE:
To evaluate how volumetric percent density (VPD) changes longitudinally with postmenopausal hormone therapy (HT).
STUDY DESIGN:
Medical records of 297 women who visited the outpatient clinic in a tertiary medical center between 2011 and 2019 were retrospectively reviewed. Study participants were postmenopausal hormone never-users (n = 103), estrogen therapy (ET) users (n = 95), and estrogen plus progestogen (EPT) users (n = 99). All hormone users were naïve to HT before the study. VPD was measured at least twice over 3 years, and was measured before and after HT in all hormone users. Longitudinal VPD changes were analyzed using a linear mixed effects model adjusted for age and body mass index (BMI) at index mammography.
RESULTS:
The mean age (standard deviation) of study participants at index mammography was 53.0 years (3.3 years). Baseline characteristics, including baseline VPD, were similar across the three groups. After adjustment for age and BMI, the predicted slopes of annual VPD change did not differ among never-users, ET users, and EPT users (-6.8 % (95 % CI -12.1 % to -1.6 %), 0.2 % (95 % CI -4.4 % to 4.8 %), and 0.4 % (95 % CI -5.1 % to 4.3 %), respectively (P = 0.21)). Furthermore, subgroup analyses stratified by estrogen formulation did not demonstrate any difference in the slopes of annual VPD change among never-users, conjugated equine estrogen users, estradiol valerate users, and EPT users (-7.0 %, -1.2 %, 4.9 %, and -0.5 %, respectively; P = 0.27).
CONCLUSION:
The predicted annual VPD change did not differ by HT during 3 years of follow-up. Neither ET nor EPT increased VPD.
2025-04-01JOURNAL OF MOLECULAR STRUCTURE
From biosynthesis to therapeutics: A comprehensive review on varied functions of estrogen and selective estrogen receptor modulators
作者: Sant, Akrati ; Ahmad, Imran ; Bhatia, Sonika ; Gupta, Atul
Estrogens are endogenous hormones vital in many physiol. functions in both sexes.An imbalance in the cumulative estrogen concentration creates many health problems, including cancers, osteoporosis, metabolic disorders, and neurol. diseases.This is often associated with the compensatory treatment of estrogen imbalances.The estradiol derivatives such as estriol (E3), mestranol, ethinyl estradiol (EE), estradiol valerate (EV), etc., per se or mainly in combination with progestogens are clin. applied to mitigate the unsubstantial feminine health.Selective estrogen receptor modulators (SERMs) are another class of therapeutics that emerged as crucial therapeutic agents offering tissue-selective estrogenic and anti-estrogenic effects, thus minimizing the undesirable side effects of steroidal therapeutics.Different classes of SERMs, including triarylethylenes, indoles, naphthalenes, and benzopyrans-based moieties, have revolutionized treatment for estrogen disorders such as osteoporosis, breast cancer, hot flashes, etc., due to their ability to modulate ER often with receptor subtype selectivity.Addnl., a combination of SERMs with Selective Estrogen Enzyme Modulators (SEEMs) particularly Aromatase Inhibitors (AIs) is also popular to tackle the clin. demand for the treatment of estrogen disorders.However, relinquishing undesirable side effects and demand for site-specific efficacy created an impetus for developing newer SERMs.An adequate understanding of estrogens, their biosynthesis, and their cognate receptors, i.e., estrogen receptors (ERs; ER-α & ER-β) is required to design or investigate an effective and safe SERM.This review delves into a discussion on the estrogens and diversified SERMs, their clin. implications in estrogen disorders, the emerging targets, and their importance.This review′s novelty relies on collating significant pieces of information and developing an understanding from the literature that renders the scope to design an effective SERM devoid of undesirable side effects.
2025-04-01SYNLETT
Diiodine–Triethylsilane System: A Practical Method for Deprotection of Aryl Benzyl Ethers
作者: Jiang, Jin ; Wang, Zhuo
Abstract:
A practical method for the debenzylation of aryl benzyl ethers has been developed using easy-to-operate I2 and Et3SiH, as well as the green solvent ethyl acetate. Halo, methoxy, ester, and nitro groups on the benzene ring of the aryl benzyl ether are compatible with this debenzylation. Control experiments revealed that Et3SiI, generated in situ, might be the actual promoter of the procedure. This method does not require a separate desilylation reaction to obtain phenol products.
100 项与 戊酸雌二醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 雌激素缺乏症状 | 中国 | 1983-01-01 | |
| 闭经 | 日本 | 1954-11-01 | |
| 更年期 | 日本 | 1954-11-01 | |
| 痛经 | 日本 | 1954-11-01 | |
| 月经过少 | 日本 | 1954-11-01 | |
| 不孕 | 日本 | 1954-11-01 | |
| 月经过多 | 日本 | 1954-11-01 | |
| 月经紊乱 | 日本 | 1954-11-01 | |
| 子宫不规则出血 | 日本 | 1954-11-01 | |
| 卵巢疾病 | 日本 | 1954-11-01 | |
| 子宫疾病 | 日本 | 1954-11-01 | |
| 低雌激素 | 美国 | 1954-07-15 | |
| 前列腺癌 | 美国 | 1954-07-15 | |
| 血管舒缩症 | 美国 | 1954-07-15 | |
| 外阴和阴道萎缩 | 美国 | 1954-07-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | - | 23 | Estradiol+Progesterone (African American Women) | 齋積範鏇夢遞繭窪願膚(衊積蓋衊構鏇鹹範構網) = 襯襯鹹範鹹觸壓壓網觸 範廠淵齋願鏇鏇淵鏇廠 (憲膚選襯積簾獵膚衊鑰, 13.3) 更多 | - | 2017-04-27 | |
Estradiol+Progesterone (Caucasian Women) | 齋積範鏇夢遞繭窪願膚(衊積蓋衊構鏇鹹範構網) = 鏇鏇鏇範鹹淵繭淵鹹鹽 範廠淵齋願鏇鏇淵鏇廠 (憲膚選襯積簾獵膚衊鑰, 11.6) 更多 | ||||||
临床3期 | 63 | (Estriol) | 蓋醖選憲廠遞製願憲選(獵簾簾蓋餘顧壓獵壓選) = 鏇簾夢餘壓鹽鬱襯網淵 繭鹹壓範鬱鏇獵簾築夢 (糧廠簾夢繭網願範願鬱, 2.3) 更多 | - | 2014-03-28 | ||
(Estradiol) | 蓋醖選憲廠遞製願憲選(獵簾簾蓋餘顧壓獵壓選) = 餘遞夢鏇鬱憲膚鑰壓築 繭鹹壓範鬱鏇獵簾築夢 (糧廠簾夢繭網願範願鬱, 3.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用